PriceTracker GLP-1

What FDA’s record states

FDA record for the warning letter to www.24hreup.biz
FieldWhat FDA’s record statesSource
Recipientwww.24hreup.bizFDA letter
LocationNot published by FDAn/a
Letter dateApr 23, 2025FDA letter
Posted by FDAJun 17, 2025FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectNotice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the InternetFDA letter
MARCS-CMS number700358FDA letter
GLP-1 drugs namedSemaglutideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“As discussed below, FDA has observed that www.24hreup.biz introduces into interstate commerce unapproved and misbranded semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products.”FDA warning letter to www.24hreup.biz, Apr 23, 2025 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters